- Home
- THAR vs HSCS Comparison
THAR vs HSCS Comparison
Compare THAR & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- HSCS
- Stock Information
- Founded
- THAR 2017
- HSCS 2007
- Country
- THAR United States
- HSCS United States
- Employees
- THAR N/A
- HSCS N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- HSCS Medical Specialities
- Sector
- THAR Health Care
- HSCS Health Care
- Exchange
- THAR Nasdaq
- HSCS Nasdaq
- Market Cap
- THAR 2.8M
- HSCS 2.7M
- IPO Year
- THAR 2022
- HSCS 2022
- Fundamental
- Price
- THAR $2.17
- HSCS $2.57
- Analyst Decision
- THAR
- HSCS Strong Buy
- Analyst Count
- THAR 0
- HSCS 1
- Target Price
- THAR N/A
- HSCS $15.00
- AVG Volume (30 Days)
- THAR 3.3M
- HSCS 28.9K
- Earning Date
- THAR 11-07-2024
- HSCS 12-12-2024
- Dividend Yield
- THAR N/A
- HSCS N/A
- EPS Growth
- THAR N/A
- HSCS N/A
- EPS
- THAR N/A
- HSCS N/A
- Revenue
- THAR N/A
- HSCS $18,600.00
- Revenue This Year
- THAR N/A
- HSCS $8,948.39
- Revenue Next Year
- THAR N/A
- HSCS $27.27
- P/E Ratio
- THAR N/A
- HSCS N/A
- Revenue Growth
- THAR N/A
- HSCS 853.85
- 52 Week Low
- THAR $1.84
- HSCS $2.36
- 52 Week High
- THAR $79.50
- HSCS $29.00
- Technical
- Relative Strength Index (RSI)
- THAR 44.85
- HSCS 36.40
- Support Level
- THAR $1.90
- HSCS $2.63
- Resistance Level
- THAR $2.33
- HSCS $2.89
- Average True Range (ATR)
- THAR 0.54
- HSCS 0.18
- MACD
- THAR -0.04
- HSCS -0.01
- Stochastic Oscillator
- THAR 6.22
- HSCS 0.69
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.